myBRCA HiRisk

A screening test that identifies mutations in 26 genes, including BRCA1 and BRCA2, which are associated with increased risk for developing breast, ovarian, and other inherited cancers.

Why should you get screened?

You might consider myBRCA HiRisk if you or one of your close blood relatives* has one or more of the following:

  • Breast cancer at or before age 50
  • 2 or more primary breast cancers in the same individual
  • Ovarian cancer, fallopian tube cancer or primary peritoneal cancer
  • Male breast cancer
  • 3 or more of the following cancers:
    Breast, ovarian, fallopian tube, primary peritoneal, endometrial, pancreatic, prostate, thyroid, colorectal, sarcoma, adrenocortical carcinoma, brain, gastric, gastrointestinal polyps, leukemia, melanoma, and/or kidney
  • A blood relative with a known cancer causing genetic mutation

* Close blood relatives: first-degree (parents, children, siblings), second-degree (grandparents, aunts/uncles, nieces/nephews, half siblings), and third degree (first cousins, great aunts/ uncles/grandparents)

The myBRCA HiRisk test will:

Help you understand your risk of developing hereditary breast, ovarian, and other inherited cancers
Help identify family members who are potentially at-risk
Improve the odds of early detection and prevention
Help guide management and/or treatment options depending on which genes are involved

If you are not at high risk but are still interested in a BRCA1 and BRCA2 screening test, please check out myBRCA.

The BRCA genes (BRCA1 and BRCA2) are part of your body’s natural defense system. They protect you from developing certain cancers. If you have a BRCA gene that is not working properly (meaning, it carries a harmful mutation), your lifetime risk of developing breast, ovarian and other cancers increases significantly.1,2

A BRCA mutation can increase the lifetime risk of breast cancer in women from 12% to up to 80% by age 80.3


general population risk

up to 80%

with BRCA mutation

A BRCA mutation can increase the lifetime risk of ovarian cancer in women from 1.3% to up to 40% by age 80.3


general population risk

up to 40%

with BRCA mutation

What you get

A Report

A report with your personal results and considerations for you to discuss with your doctor

Genetic Counseling

A complimentary call with one of our genetic counselors to review your results upon request (currently applies to US only)

Valuable Insights

Insights to help you and your doctor determine the most appropriate preventive, clinical, and lifestyle considerations based on your hereditary risk.


Comprehensive analysis of 26 genes associated with hereditary breast and ovarian cancer.

The myBRCA HiRisk test screens these 26 genes:


These genes may also be associated with increased risk for:

Cancer Types
  • Colorectal cancer
  • Endometrial cancer
  • Melanoma
  • Pancreatic cancer
  • Gastric cancer
  • Others
Hereditary Cancer Syndromes
  • Cowden syndrome
  • Li-Fraumeni syndrome
  • Peutz-Jeghers syndrome
  • Lynch syndrome
  • Others

How to get started

Order the test

Talk to your doctor about ordering the myBRCA HiRisk test for you.

Collect your sample

Your sample is collected per your physician's instructions

Sample is processed

Once we receive your sample, we process it at our CLIA lab and provide results within 4-5 weeks

Your report is ready

We let you and your doctor know that your results are ready on our secure site

Additional information

Find out more about possible outcomes and other technical information.

  • Any result, negative, positive, or inconclusive, should become a part of how you and your doctor evaluate your health and clinical needs.
  • You can download this written summary for an explanation of how myBRCA HiRisk testing works and what your potential outcomes could mean.
  • Targeted next generation sequencing assay for 26 hereditary cancer genes.
  • BRCA1 and BRCA2 large rearrangement analysis included (>99.9% sensitivity and specificity).
  • Point mutations and small insertions/deletions are detected (>99.9% sensitivity and specificity)
  • Likely pathogenic or pathogenic intronic variants up to 10 base pairs from the coding region are always reported
  • Variant classification based on ACMG Guidelines

Want to stay up to date with myBRCA HiRisk?

Let us know and our team will get in touch with you.

  1. National Cancer Institute. BRCA1 & BRCA2: Cancer Risk & Genetic Testing. 2015.NCI
  2. American Cancer Society. Breast cancer risk factors you cannot change. 2015.ACS
  3. Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from:NCBI